S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models.
Lauren R BeggAdrienne M OrriolsMarkella ZannikouChen YehPranathi VadlamaniDeepak KanojiaRosemary BolinSara F DunneSanjeev BalakrishnanRoman CamardaDiane RothNicolette A Zielinski-MoznyChristina YauAthanassios VassilopoulosTzu-Hsuan HuangKwang-Youn A KimDai HoriuchiPublished in: Communications medicine (2024)
Our data propose S100A8/A9 as a potential predictive and pharmacodynamic biomarker in clinical trials evaluating combination therapy targeting PIM and immune checkpoints in TNBC. This work encourages the development of S100A8/A9-based liquid biopsy tests for treatment guidance.